A Phase I clinical study of ER+ and HER2- breast cancer patients who had received an average of five continuous treatments showed that ARV-471 could significantly reduce the expression level of ER in tumor tissue of patients, reducing the ER level by 62% on average, up to 90% at most. This evidence concerns the gene ESR1 and breast cancer.